@article{oai:niigata-u.repo.nii.ac.jp:00011481,
 author = {成田, 美和子},
 issue = {11},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {Nov},
 note = {The history of treatments for chronic myelogenous leukemia (CML) represents a success story caused by the development of molecular medicine. Imatinib myslate (Glivec), a tyrosine kinase inhibitor targeting the Bcr-Abl oncoprotein, which is associated with the pathogenesis of CML and the most specific marker of CML, has induced not only hematological and cytogenetic remissions but surprising genetic response in the patients of CML in all phases. In this report we present the mechanism of action of imatinib, detection methods of Ph clone used for the evaluation of the effects of imatinib treatment, clinical results of imatinib therapy in Niigata Glivec Study Group, future problems and novel kinase inhibitors nilotinib and dasatinib. Stern cell transplantation remains to be a useful option for getting into the level of complete genetic cure although it has been not generally used as first-line treatment already. Within several years many treatment methods will be available for patients with CML, so standardizes and quantitative methods have to be arranged to clarify the effectiveness of targeting therapy.},
 pages = {601--611},
 title = {2 慢性骨髄性白血病に対するイマチニブ治療(シンポジウム がんの分子標的治療, 第628回新潟医学会)},
 volume = {121},
 year = {2007}
}